NXL
Nexalin Technology, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.79
P/S
24.57
EV/EBITDA
-0.82
DCF Value
$-0.24
FCF Yield
-66.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-310.3%
Operating Margin
-2781.7%
Net Margin
-2725.8%
ROE
-195.7%
ROA
-177.4%
ROIC
-223.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $171.9K | $-2.4M | $-0.13 |
| FY 2025 | $301.6K | $-8.2M | $-0.50 |
| Q3 2025 | $18.1K | $-2.3M | $-0.13 |
| Q2 2025 | $70.6K | $-1.6M | $-0.10 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
4.23
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.